4篇
您的检索式：作者名="Simon Witzel"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Neuroflament light and heterogeneity of disease progression in amyotrophic lateral sclerosis:development and validation of a prediction model to improve interventional trials显示文摘Background:Interventional trials in amyotrophic lateral sclerosis(ALS)sufer from the heterogeneity of the disease as it considerably reduces statistical power.We asked if blood neuroflament light chains(NfL)could be used to antici‑pate disease progression and increase trial power.Methods:In 125 patients with ALS from three independent prospective studies-one observational study and two interventional trials-we developed and externally validated a multivariate linear model for predicting disease pro‑gression,measured by the monthly decrease of the ALS Functional Rating Scale Revised(ALSFRS-R)score.We trained the prediction model in the observational study and tested the predictive value of the following parameters assessed at diagnosis:NfL levels,sex,age,site of onset,body mass index,disease duration,ALSFRS-R score,and monthly ALSFRS-R score decrease since disease onset.We then applied the resulting model in the other two study cohorts to assess the actual utility for interventional trials.We analyzed the impact on trial power in mixed-efects models and compared the performance of the NfL model with two currently used predictive approaches,which anticipate disease progression using the ALSFRS-R decrease during a three-month observational period(lead-in)or since disease onset(ΔFRS).Results:Among the parameters provided,the NfL levels(P<0.001)and the interaction with site of onset(P<0.01)contributed signifcantly to the prediction,forming a robust NfL prediction model(R=0.67).Model application in the trial cohorts confrmed its applicability and revealed superiority over lead-in andΔFRS-based approaches.The NfL model improved statistical power by 61%and 22%(95%confdence intervals:54%-66%,7%-29%).Conclusion:The use of the NfL-based prediction model to compensate for clinical heterogeneity in ALS could signif‑cantly increase the trial power.NCT00868166,registered March23,2009;NCT02306590,registered December 2,2014. | Simon Witzel Felix Frauhammer† Petra Steinacker David Devos Pierre‑François Pradat Vincent Meininger Stefen Halbgebauer Patrick Oeckl Joachim Schuster Simon Anders Johannes Dorst Markus Otto Albert C.Ludolph | 2021 | Translational Neurodegeneration2021，10，3： | 1 |
| 2 | Prednisone reduces muscle degeneration in dystrophin-deficient Caenothabditis elegans 显示文摘 | Gaud A Simon JM Witzel T | 2004 | Neuromuscul Disord2004，14，6： | 1 |
| 3 | Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans 显示文摘 | Gaud A Simon JM Witzel T | 2004 | Neuromuscul Disord2004，14，： | 1 |
| 4 | Prednisone reduces muscle degeneration in dystrophin - deficient Caenorhabiditis elegans 显示文摘 | Gaud A Simon JM Witzel T | 2004 | Neuromuscul Disord2004，14，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员